On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to corticosteroids or cannot tolerate a corticosteroid taper. The regulatory decision establishes Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic for PMR, giving rheumatologists an alternative to long-term steroid therapy backed by...
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg ...
By Dhallo News · November 17, 2026 at 7:54 PM IST
Have feedback on this article?Report error or suggestion
